Author(s): Chen, RH (Chen, Rong-Hsing); Chang, CT (Chang, Chwen-Tzuei); Wang, TY (Wang, Tzu-Yuan); Huang, WL (Huang, Wen-Liang); Tsai, CH (Tsai, Chang-Hai); Tsai, FJ (Tsai, Fuu-Jen)
Title: p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases Source: JOURNAL OF CLINICAL LABORATORY ANALYSIS, 22 (5): 321-326 2008 Language: English
Document Type: Article
Author Keywords: autoimmune thyroid diseases; Graves' disease; Hashimoto's thyroiditis;
p53; polymorphism
KeyWords Plus: HASHIMOTOS-THYROIDITIS; CELL SUICIDE; APOPTOSIS;
SUSCEPTIBILITY; CANCER; RISK; GENE; CYTOTOXICITY; PATHOGENESIS;
CARCINOMA
Abstract: p53 protein participates in the processes of apoptosis, which is involved in a number of immunological reactions. In order to test whether the p53 gene could be used as a genetic marker for the prediction of the development of autoimmune thyroid diseases (AITD), we screened, by using polymerase chain reaction (PCR) analysis, for the C (CCC)/G (CGC) polymorphism at the p53 codon 72 (Pro 72/Arg 72) to determine the genotypes of 107 Hashimoto's thyroiditis (HT) and 90 Graves' disease (GD) patients, and 105 normal controls.
The data demonstrated that, for the genotype analysis, HT patients featured an enhanced numerical ratio for the Arg/Arg homozygous genotype (33.7%) and a diminished ratio for the Arg/Pro heterozygous genotype (41.1%) at the p53 codon 72 than was the case for normal controls (Arg/Arg: 17.1% and Arg/Pro: 61.9%; P = 0.005). The odds ratio for the risk of the Arg/Arg genotype's appearance, compared with that of the Arg/Pro and Pro/Pro genotypes combined, for the HT patient group was 2.450 (95% confidence interval: 1.274-4.716). With respect to allelic analysis, we did not observe significant difference in the frequency of appearance of the Arg allelic variant and the Pro allelic variant for the p53 codon 72 when comparing the HT patient group with the control group (P = 0.208). On the other hand, GD patients presented no significant difference in distribution for both genotype and allelic frequencies (P=0.344 and 0.245, respectively) when compared with normal controls. In conclusion, HT patients feature a greater ratio of arginine homozygosity at p53 codon 72 than in the case for normal subjects. The p53 codon 72 proline/arginine polymorphism may be a genetic marker to predict the increased susceptibility of development of HT.
Addresses: [Chen, Rong-Hsing; Chang, Chwen-Tzuei; Wang, Tzu-Yuan; Huang, Wen-Liang]
China Med Univ, China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Chen, Rong- Hsing] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung, Taiwan; [Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ, China Med Univ Hosp, Dept Med Genet, Taichung, Taiwan; [Tsai, Chang-Hai] Asia Univ, Dept Bioinformat, Taichung, Taiwan
Reprint Address: Tsai, FJ, 2 Yuh Der Rd, Taichung 404, Taiwan.
E-mail Address: [email protected]
Cited References: ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961.
BENNETT M, 1998, SCIENCE, V282, P290.
BOLTZE C, 2002, INT J ONCOL, V21, P1151.
CHETTY R, 1995, J CLIN PATHOL, V48, P239.
CHIOVATO L, 1993, J CLIN ENDOCR METAB, V77, P1700.
DHEIN J, 1995, NATURE, V373, P438.
DUKE RC, 1996, SCI AM, V275, P80.
DUMONT P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093.
FENTON CL, 2000, ANN CLIN LAB SCI, V30, P179.
GIORDANO C, 1997, SCIENCE, V275, P960.
GRANJA F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016.
JEFFREY PD, 1995, SCIENCE, V267, P1498.
JIN XM, 1995, CARCINOGENESIS, V16, P2205.
KARP G, 2002, CELL MOL BIOL CONCEP, P32.
KARP G, 2002, CELL MOL BIOL CONCEP, P671.
KOTANI T, 1995, AUTOIMMUNITY, V20, P231.
LARSEN PR, 1987, ARCH PATHOL LAB MED, V111, P1141.
LIVOLSI VA, 2000, WERNER INGBARS THYRO, P488.
LOWE SW, 1993, CELL, V74, P957.
MARTINEZ A, 1992, TORTURE, V2, P47.
OKAYASU I, 1998, CLIN IMMUNOL IMMUNOP, V88, P183.
ROMAGNANI S, 1996, CLIN IMMUNOL IMMUN 1, V80, P225.
STOREY A, 1998, NATURE, V393, P229.
TANIMOTO C, 1995, ENDOCR J, V42, P193.
TOMER Y, 2003, ENDOCR REV, V24, P694, DOI 10.1210/er.2002-0030.
WEETMAN AP, 1992, CLIN ENDOCRINOL, V36, P307.
WOOLNER LB, 1959, J CLIN ENDOCR METAB, V19, P53.
YANAGAWA T, 1997, THYROID, V7, P843.
YU MW, 1999, HEPATOLOGY, V29, P697.
ZAMZAMI N, 2005, BIOCHEM BIOPH RES CO, V331, P685.
Cited Reference Count: 30 Times Cited: 1
Publisher: WILEY-LISS
Publisher Address: DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
ISSN: 0887-8013 DOI: 10.1002/jcla.20249
29-char Source Abbrev.: J CLIN LAB ANAL ISO Source Abbrev.: J. Clin. Lab. Anal.
Source Item Page Count: 6
Subject Category: Medical Laboratory Technology ISI Document Delivery No.: 356CJ
